New biologic drug netakimab tested in kids with psoriasis

NCT ID NCT06640517

Ongoing Disease control Sponsor: Biocad Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests the drug netakimab in children aged 6 and older with moderate to severe plaque psoriasis. The study compares netakimab to a placebo and also includes an open-label group receiving adalimumab. The main goal is to see if netakimab improves skin symptoms, measured by the Psoriasis Area and Severity Index (PASI75) and a physician's global assessment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: netakimab
What this could lead to: If it works, this could offer a new treatment option for children with moderate to severe plaque psoriasis, helping clear skin and reduce symptoms.
What could go wrong: This is a phase 3 trial, but results are not yet published. The drug may not work better than placebo, and side effects like infections or allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Federal State Autonomous Institution "National Medical Research Center for Children's Health" of the Ministry of Health of the Russian Federation

Moscow, Russia
Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation

Barnaul, Russia
Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Health of the Russian Federation

Kirov, Russia
Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University"

Tomsk, Russia
Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation

Tomsk, Russia
Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation

Saint Petersburg, Russia
Federal State Budgetary Institution "State scientific centre of dermatovenerology and cosmetology" of the Ministry of health of Russian Federation, Nizhny Novgorod branch

Nizhny Novgorod, Russia
Limited Liability Company "Health Azbuka Medical Center"

Kazan', Russia
Limited Liability Company "PiterKlinika"

Saint Petersburg, Russia
State Autonomous Healthcare Institution "Kuzbass Clinical Dermatovenerological Dispensary"

Kemerovo, Russia
State Autonomous Healthcare Institution "Republic Clinical Dermatovenerologic Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor Ge"

Kazan', Russia
State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary"

Chelyabinsk, Russia
State budgetary healthcare institution "Clinical Dermatovenerologic Dispensary" of the Ministry of Health of the Krasnodar Territory

Krasnodar, Russia
State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology"

Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.